Iguratimod for Sjögren’s syndrome symptoms and safety
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial studies whether iguratimod improves symptoms in people with primary Sjögren’s syndrome, and checks how safe it is. It focuses on people with confirmed disease markers (anti-SSA/Ro-60) and ongoing dry eyes and dry mouth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary Sjögren’s syndrome diagnosed using 2016 ACR/EULAR criteria
- You have dry eyes and dry mouth symptoms
- Your blood test shows anti-SSA/Ro-60 antibodies are positive
- Your IgG level is at least 16 g/L
- You haven’t taken hormones, immunosuppressants, biologic medicines, or other study drugs in the last 4 weeks
- If you are able to become pregnant: your pregnancy test is negative and you can use reliable birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This study looks at an immune reaction (called anti-Ro/SSA IgE) to see how active primary Sjögren’s disease is. It may help doctors better understand what’s driving symptoms and activity levels over time.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
This study tests whether upadacitinib, a pill that reduces inflammation, can help people with Sjögren's syndrome. It aims to see if the drug can lower disease activity and improve symptoms.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
Hear when a new Primary Sjögren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.